Cited by 524Diabetes Treatment and ManagementLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes

Open access

Tiikkainen, Mirja, Häkkinen, Anna-Maija, Korsheninnikova, Elena, Nyman, Tuulikki, Mäkimattila, Sari, Yki-Järvinen, Hannele·2004·Diabetes

DOI 10.2337/diabetes.53.8.2169

Open this paper in CoChat — free account Open PDF

Abstract

Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans. The objective of this study was to compare the effects of rosiglitazone and metformin treatment on liver fat content, hepatic insulin sensitivity, insulin clearance, and gene expression in adipose tissue and serum adiponectin concentrations in type 2 diabetes. A total of 20 drug-naive patients with type 2 diabetes (age 48 +/- 3 years, fasting plasma glucose 152 +/- 9 mg/dl, BMI 30.6 +/- 0.8 kg/m2) were treated in a double-blind randomized fashion with either 8 mg rosiglitazone or 2 g metformin for 16 weeks. Both drugs similarly decreased HbA1c, insulin, and free fatty acid concentrations. Body weight decreased in the metformin (84 +/- 4 vs. 82 +/- 4 kg, P < 0.05) but not the rosiglitazone group. Liver fat (proton spectroscopy) was decreased with rosiglitazone by 51% (15 +/- 3 vs. 7 +/- 1%, 0 vs. 16 weeks, P = 0.003) but not by metformin (13 +/- 3 to 14 +/- 3%, NS). Rosiglitazone (16 +/- 2 vs. 20 +/- 1 ml.kg(-1).min(-1), P = 0.02) but not metformin increased insulin clearance by 20%. Hepatic insulin sensitivity in the basal state increased similarly in both groups. Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Serum adiponectin concentrations increased by 123% with rosiglitazone but remained unchanged during metformin treatment. The decrease of serum adiponectin concentrations correlated with the decrease in liver fat (r = -0.74, P < 0.001). Rosiglitazone but not metformin significantly increased expression of peroxisome proliferator-activated receptor-gamma, adiponectin, and lipoprotein lipase in adipose tissue. In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance. The decrease in liver fat by rosiglitazone is associated with an increase in serum adiponectin concentrations. Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diabetes.53.8.2169

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,673
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
Combs, T. P., Berg, A. H., Obici, S., Scherer, P. E., & Rossetti, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14120 · Cited by 955
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794

Show all 48 references

Sorted by citations

Items 401–500 of 524

Transcriptomic Analysis of Insulin-Sensitive Tissues from Anti-Diabetic Drug Treated ZDF Rats, a T2DM Animal Model
Kim, Y. N., Kim, S., Kim, I.-Y., Shin, J. H., Cho, S., Yi, S. S., Kim, W., Kim, K., Lee, S., & Seong, J. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069624 · Cited by 5
Oral Agents in Managing Diabetes Mellitus in Children and Adolescents
Jacobson-Dickman, E. E., & Levitsky, L. L. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.008 · Cited by 5
Glucose Supply and Insulin Demand Dynamics of Antidiabetic Agents
Monte, S. V., Schentag, J. J., Adelman, M. H., & Paladino, J. A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400219 · Cited by 5
Safety evaluation and antihyperglycaemic effect of root extract of Maerua decumbens (Brongn.) DeWolf in Wistar rats
Kiptisia, R. T., Maiyoh, G. K., Macharia, B., & Tuei, V. C. (2020) · Scientific African · doi:10.1016/j.sciaf.2020.e00379 · Cited by 5
Metformin: Pros and Cons
Sivadasan, S., Subramanian, M., & Aiyalu, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99815 · Cited by 5
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
Mankieva, E., & Ивановна, К. Е. (2023) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro202312041103 · Cited by 5
Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview.
Nagata, K., & Hattori, T. (2011) · PubMed Central · doi:10.18999/nagjms.73.3-4.91 · Cited by 5
Nonviral Hepatitis
Wilbur, K. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190008328694 · Cited by 5
Adipokines regulate systemic insulin sensitivity in accordance to existing energy reserves
Huypens, P. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2006.10.053 · Cited by 5
Methodological Considerations in Human Studies of Gene Expression in HIV-Associated Lipodystrophy
Mallon, P. W. G., Sedwell, R., Unemori, P., Kelleher, A. D., Cooper, D. A., & Carr, A. D. (2005) · Antiviral Therapy · doi:10.1177/135965350501002s11 · Cited by 5
A Comparison of the Therapeutic Effects of Metformin, Pioglitazone and Vitamin E in Patients with Non-Alcoholic Fatty Liver
Shahebrahimi, K., Zulnoorian, S., Almasi, A., Sharifi, A., Keshvarz, A., & Farshchian, N. (2017) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 5
Pharmacological Prevention of Type 2 Diabetes
Scheen, A. J. (2008) · Wiley eBooks · doi:10.1002/9780470779750.ch29 · Cited by 5
Translational control of murine adiponectin expression by an upstream open reading frame element
Vasu, K. I., Ramachandiran, I., Chechi, A., Khan, K., Khan, D., Kaufman, R. J., & Fox, P. L. (2023) · RNA Biology · doi:10.1080/15476286.2023.2256094 · Cited by 4
Role of PPARγ, a transcription factor in cardiovascular disease
Mukohda, M. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.56 · Cited by 4
Evaluation of the Vasoprotective Effects of Metformin versus Glibenclamide in Type 2 Diabetic Patients
Fathi, Z. H., Mohammad, J. A., & Mohammed, M. H. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.01108 · Cited by 5
Glycemic Control in the Metabolic Syndrome and Implications in Preventing Cardiovascular Disease
Gerich, J. E. (2006) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2006.4.315 · Cited by 4
Combined Pioglitazone and Metformin Treatment Maintains the Beneficial Effect of Short-Term Insulin Infusion in Patients with Type 2 Diabetes: Results from a Pilot Study
Musholt, P. B., Schöndorf, T., Pfützner, A., Hohberg, C., Kleine, I., Fuchs, W. A., Hehenwarter, S., Dikta, G., Kerschgens, B., & Forst, T. M. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300626 · Cited by 4
Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight in the global cardiometabolic risk
Calabrò, P., & Yeh, E. T. H. (2007) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-007-0006-8 · Cited by 4
The PPARγ ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARγ in the subcutaneous adipose tissue
Joosen, A. M. C. P., Bakker, A. H. F., Kersten, S., & Westerterp, K. R. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114507824081 · Cited by 5
Adipose Tissue and Type 2 Diabetes Mellitus
WAJCHENBERG, B. L., & COHEN, R. V. (2014) · Humana Press eBooks · doi:10.1007/978-1-62703-770-9_16 · Cited by 4
Peroxisome Proliferator–Activated Receptors and The Metabolic Syndrome
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i1.79 · Cited by 4
A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Effects of Biguanides (Metformin) and Thiazolidinediones on Glucose Tolerance and Insulin Sensitivity in Patients With Type II Diabetes Mellitus
Zaki, H. A., Iftikhar, H., Shallik, N. A., Shaban, E. E., Al-Marri, N. D. R., Bashir, I., Elhadad, A., Zoghlami, F., & Abdalrubb, A. (2023) · Cureus · doi:10.7759/cureus.39445 · Cited by 3
[Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
Jansen, P. L. M. (2005) · PubMed · Cited by 3
Inhibition of protein kinase B by palmitate in the insulin signaling of HepG2 cells and the preventive effect of arachidonic acid on insulin resistance
Xia, Y., Wan, X.-D., Duan, Q., He, S., & Wang, X. (2007) · Frontiers of Medicine · doi:10.1007/s11684-007-0038-y · Cited by 3
Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance
Bloomgarden, Z. T. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.316 · Cited by 3
Nonalcoholic Fatty Liver Disease
Stefan, N., & Häring, H. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50024-3 · Cited by 3
Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Bril, F., Ntim, K., Lomonaco, R., & Cusi, K. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch20 · Cited by 3
Safety and efficacy modelling in anti-diabetic drug development.
Hamrén, B. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 3
Acute exposure to rosiglitazone does not affect glucose transport in intact human skeletal muscle
Skrobuk, P., Kuoppamaa, H., Hiukka, A., & Koistinen, H. A. (2009) · Metabolism · doi:10.1016/j.metabol.2009.07.016 · Cited by 2
Mapping the global research landscape on nonalcoholic fatty liver disease and insulin resistance: A visualization and bibliometric study
Zyoud, S. H., Hegazi, O. E., Alalalmeh, S. O., Shakhshir, M. H., Abushamma, F., Khilfeh, S., & Al‐Jabi, S. W. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i6.951 · Cited by 2
Hígado graso no alcohólico: ¿un componente inflamatorio del síndrome metabólico?
Almarza, J. (2011) · Perspectivas en Nutrición Humana · doi:10.17533/udea.penh.9571 · Cited by 2
Endocrine Disorders and the Heart
Lavis, V. R., Picolos, M. K., & Willerson, J. T. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_111 · Cited by 2
Esteatosis hepática y resistencia a la insulina: ¿qué ocurre primero?
Esteve-Lafuente, E., & Ricart, W. (2006) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(06)73708-1 · Cited by 2
Pharmacological agents for nonalcoholic steatohepatitis
Guillaume, M., & Ratziu, V. (2013) · Hepatology International · doi:10.1007/s12072-013-9482-8 · Cited by 2
Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis
Vergès, B. L., Petit, J.-M., & Bouillet, B. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.11.001 · Cited by 2
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L., Lundbom, N. M. I., Rissanen, A., Ridderstråle, M., & Groop, L. (2009) · Cited by 2
NASH
Neuschwander‐Tetri, B. A. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50060-7 · Cited by 2
Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone
Sun, Y., Yu, Q., & Xie, J. (2020) · Cellular and Molecular Biology · doi:10.14715/cmb/2020.66.6.5 · Cited by 2
Pharmacotherapy of Childhood Obesity and Pre-diabetes
Freemark, M. (2010) · Springer eBooks · doi:10.1007/978-1-60327-874-4_23 · Cited by 2
NHG-Standaard Diabetes mellitus type 2
Rutten, G. E. H. M., Grauw, W. D., Nijpels, G., Goudswaard, A., Uitewaal, P. J. M., der Does, F. V., Heine, R. J., van Ballegooie, E., Verduijn, M., & Bouma, M. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_69 · Cited by 2
Rosiglitazone and lipid metabolism
Ferrannini, E. (2004) · Diabetologia · doi:10.1007/s00125-004-1616-z · Cited by 2
Non-Alcoholic Fatty Liver Disease : A clinical and histopathological study
Ekstedt, M. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Postprandial Dysmetabolism and Non-Alcoholic Fatty Liver Disease in Relation to Type 2 Diabetes Mellitus and Cardiovascular Risk
Schindhelm, R. K. (2007) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · Cited by 2
Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study
Tosi, F., Zanolin, M. E., Garofalo, S., Gremes, V., Zoppini, G., & Moghetti, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02800-4 · Cited by 1
A substrate-competition hypothesis for type 2 diabetes driven by nutrient excess rather than a primary insulin-signaling defect
Poothullil, J. M. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.111926 · Cited by 1
Adiponectine et syndrome métabolique
Kim, M. J., Maachi, M., Capeau, J., & Bastard, J. (2006) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2005.12.001 · Cited by 1
Combination of nateglinide with thiazolidinediones in Type 2 diabetes
Voulgari, C., & Tentolouris, N. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.40 · Cited by 1
Le syndrome métabolique en 2006
Ducluzeau, P. (2006) · Médecine du Sommeil · doi:10.1016/s1769-4493(06)70081-4 · Cited by 1
Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes
Yeap, P. M., Lockman, K. A., Elton, R. A., Boyd, M., Hayes, P. C., & Jaap, A. J. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411402630 · Cited by 1
Novel Anti-Diabetic Formula: Recover Islet ?-Cell dysfunction with the implementation of molecular approach
Kosta, S., Dangi, C. B. S., Shekhar, C., Kaur, M., Malviya, S. N., Tiwari, M. L., Khan, S., & Kapoor, S. (2015) · International Journal of Advances in Scientific Research · doi:10.7439/ijasr.v1i2.1799 · Cited by 1
Long term effects of pioglitazone therapy with nonalcoholic steatohepatitis
Nakayama, H., Iwahasi, S., Ojima, T., Kusano, M., Asano, S., & Sugai, Y. (2009) · Kanzo · doi:10.2957/kanzo.50.555 · Cited by 1
Adipose Tissue Gene Expression in the Context of Inflammation and Obesity
Kern, P. A. (2006) · CRC Press eBooks · doi:10.1201/9781420005905.ch6 · Cited by 1
Anti-Diabetic Effects of Niclosamide Ethanolamine and Metformin in Mouse Models
(2017) · doi:10.29199/demd.101014
The Patients at High Risk of Type 2 Diabetes Development
Иванникова, Е. В., & Smirnova, O. M. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-26-50-55 · Cited by 1
Non alcoholic fatty liver disease (NAFLD): an overview
McAvoy, N., Lockman, A., & Hayes, P. C. (2007) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520073701003 · Cited by 1
Lechenie sakharnogo diabeta 2-go tipa tiaglitazonami; vliyanie na sostoyanie serdechno-sosudistoy sistemy
Britov, A. N. (2008) · Obesity and metabolism · doi:10.14341/2071-8713-5221 · Cited by 1
PPARs in Viral Disease
Capeau, J., Serfaty, L., & Badr, M. Z. (2009) · PPAR Research · doi:10.1155/2009/393408 · Cited by 1
Abnormalities of Carbohydrate Metabolism and the Liver
Sundaram, S. S., & Alonso, E. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0774-8.10073-9 · Cited by 1
EVALUATION OF GHRELIN, INSULIN AND LEPTIN LEVELS IN OBESE TYPE 2 DIABETIC PATIENTS ON METFORMIN OR GLIMEPIRIDE THERAPY IN BASRA, IRAQ
Jaccob, A. A., Sheri, F. H., & Aljazaeari, Q. A. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Glucose and lipid metabolism in human skeletal muscle
Skrobuk, P. (2012) · Työväentutkimus Vuosikirja · Cited by 1
Fatty acid and glucose metabolism in upper body obesity : effects of diet and exercise compared to pioglitazone administration
Shadid, S. (2007) · Research Publications (Maastricht University) · doi:10.26481/dis.20070523ss · Cited by 1
Peut-on traiter la stéatohépatite métabolique ?
Ratziu, V., Vispo, M., Tahiri, M., Bonyhay, L., de Torres, M., Bernhardt, C., Poynard, T., & Lebray, P. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89386-9 · Cited by 1
ADIPOCYTE-DERIVED HORMONES AND CARDIOVASCULAR DISEASE
Eriksson, M. (2010) · DiVA at Umeå University (Umeå University) · Cited by 1
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Insulin Resistance
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch31 · Cited by 1
Diet Induced Obesity Alters Muscle Spindle Afferent Function in Adult Mice
Elahi, L. S. (2017) · doi:10.31979/etd.5hc9-8tjn · Cited by 1
Avaliação da resistência à insulina em pacientes com hepatite C crônica não diabéticos
Vallenas, M. C. T. (2013) · doi:10.11606/d.5.2013.tde-26092013-145111
Estrés quirúrgico durante el bypass gástrico en obesos mórbidos
Déniz, J. R. (2010) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Insulin therapy in type 2 diabetes : Initiation, impact on liver fat, role of combination therapy with glitazones or glindes
Juurinen, L. (2014) · Työväentutkimus Vuosikirja
LIVER FAT IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES
Kotronen, A. (2008) · Työväentutkimus Vuosikirja
Treatment of the Obese Patients With Type 2 Diabetes
Chan, J. L., Mantzoros, C. S., & Abrahamson, M. J. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-985-1_27
A manutenção do tecido adiposo é fundamental para o controle metabólico do diabetes mellitus induzido em ratos.
Takada, J. (2008) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2008.tde-04082008-130026
Adipose tissue inflammation, hepatic fat accumulation and insulin resistance
Kolak, M. (2008) · Figshare
Is a non-alcoholic fatty liver an inflammatory component of the metabolic syndrome?
Almarza, J. (2011) · Vitae (Universidad de Antioquia)
The effectiveness of metformin in patients with metabolic syndrome and nonalcoholic fatty liver disease
Бутрова, С. А., Eliseeva, A. Y., & Ильин, А. В. (2008) · Obesity and metabolism · doi:10.14341/omet2008217-21
Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus
Derosa, G., SALVADEO, S. A. T., & Cicero, A. F. G. (2006) · Therapy · doi:10.1586/14750708.3.5.559
Nonalcoholic Fatty Liver Disease in Pediatric Patients
Sundaram, S. S., & Nadeau, K. J. (2009) · Obesity Management · doi:10.1089/obe.2009.0206
Nealkogol'naya zhirovaya bolezn' pecheni: aktual'nye proekty
Бутрова, С. А., & Eliseeva, A. Y. (2007) · Obesity and metabolism · doi:10.14341/2071-8713-5155
Clinical and Economic Evaluation of Two Thiazolidinediones in the Management of Diabetes
Shaya, F. T., Calloway, S., Pharmd, C., Khoury, A. C. E., Tomety, J., & Pharmd, C. (2015)
Perinatal essential fatty acid deficiency in mice - effects on metabolism and behaviour
Pálsdóttir, V. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University)
IMPACT OF CURRENT DIABETES THERAPIES ON MACROVASCULAR OUTCOMES
Wysham, C. (2006)
Régulation de protéine C-réactive vasculaire dans le diabète de type 2
Mugabo, Y. (2010) · doi:10.71781/27620
Novel pharmaceutical approaches to regulate glucose homeostasis
Sundbom, M. (2010) · Figshare
Non-Alcoholic Fatty Liver Disease: Pathogenesis Directed Therapy – the Way Forward
McAvoy, N. C., Lockman, A., & Hayes, P. C. (2007) · Hungarian Medical Journal · doi:10.1556/hmj.1.2007.2.5
Pioglitazone and Nonalcoholic Steatohepatitis
Boden, G. H. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0034-2
The effect of metformin on vascular function and AMP-activated protein kinase activation in Type 2 diabetes
Boyle, J. G. (2009) · Enlighten: Theses (The University of Glasgow)
IS THERE AN INTRINSIC VASCULAR BENEFIT TO TZDs? EXAMINING THE EVIDENCE *
Tg, B., Bartol, T. G., Wysham, C., & White, K. M. (2006)
Treatment with Thiazolidinediones
Suvag, S., Utzschneider, K. M., & Kahn, S. E. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_9
Nutritional regulation of central fat mass and obesity-associated (FTO) expression, and its association with the central melanocortin signaling in the regulation of energy homeostasis
Poritsanos, N. J. (2010) · Mspace (University of Manitoba)
Bewegungstherapeutische Effekte bei Patienten mit gestörter Glukosetoleranz
Lehmann, S. (2010) · Qucosa (Saxon State and University Library Dresden)
Avaliação de atividade antioxidante e atividade agonista em receptores nucleares PPARα β/δ e γ de metabólitos de fungos endofíticos isolados de folhas da Bauhinia variegata
Mesquita, P. G. (2015) · doi:10.26512/2015.08.t.19730
Pioglitazone therapy could improve histology of a lean patient with advanced nonalcoholic steatohepatitis. A case report
Nakayama, H., Ikeya, S., Okamoto, D., Komazawa, D., Watanabe, T., Itou, H., Tosa, M., Dairaku, N., Ikeda, T., Takahashi, S., et al. (2014) · Kanzo · doi:10.2957/kanzo.55.57
Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
Schinner, S. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79332-1
Sociedade Brasileira de Cardiologia Brazilian Society of Cardiology Conselho Editorial Editorial Board
Mesquita, E. T., Junior, C. V. S., de Suplemento, Guimarães, J. I., Liberman, B., Mansur, A. J., Sousa, A. G. M. R., Sposito, A. C., Rassi, A., Lopes, A. A., et al. (2005)
Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_16
Место метформина в современном лечении и профилактике сахарного диабета 2 типа
Smirnova, O. M. (2010) · CyberLeninK (CyberLeninka)
COMISSÃO DE REDAÇÃO
de Cardiologia, S. B., Simão, A. F. L., Cunha, V., Guimarães, C., Brandão, A. P., Brandão, A. A., Nogueira, A. D. R., Suplicy, H., & Guimarães, J. I. (2005)
Update of the evidence-based guideline of the German Diabetes Association
Matthaei, S., Bierwirth, R., Fritsche, A., Häring, U., Kellerer, M., Kunt, T., Schernthaner, G., Siegel, E. G., & Thienel, F. (2008)
Overview of insulin resistance and the metabolic syndrome
Sattar, N. A., & Mukhopadhyay, B. (2003) · CRC Press eBooks · doi:10.3109/9780203481165-13

Authors: Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H.
Affiliations: University of Helsinki (FI)
Department of Medicine, Division of Oncology, University of Helsinki, Helsinki, Finland
Minerva Foundation (FI)
Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
Venue: Diabetes
Publisher: American Diabetes Association
Published: 2004-08-01
Volume: 53
Issue: 8
Pages: 2169-2176
ISSN: 0012-1797 (ISSN-L)
1939-327X
DOI: 10.2337/diabetes.53.8.2169
OpenAlex: W2107068945
Cited by: 524
References: 48
Citations by year: 2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 15 · 2017: 12 · 2016: 18 · 2015: 19 · 2014: 24 · 2013: 26 · 2012: 15
FWCI: 34.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes (publishedVersion)
PubMed (publishedVersion)
Funders: Suomen Lääketieteen Säätiö
Biomedicum Helsinki-säätiö
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords: rosiglitazone, metformin, type 2 diabetes, hepatic insulin resistance, hepatic insulin sensitivity, liver fat, insulin clearance, adiponectin, adipose tissue gene expression, PPARγ, lipoprotein lipase, insulin-stimulated glucose uptake, 1H NMR, drug comparison, weight loss, HbA1c
MeSH terms: Rosiglitazone, Adipose Tissue, Cholesterol, Diabetes Mellitus, Type 2, Female, Gene Expression Regulation, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Male, Metformin, Middle Aged, Triglycerides, Thiazolidinediones, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks